Vifor vs. Orbicular: Ferric Carboxymaltose Patent Dispute Settled in NJ District Court
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Vifor (International) AG v. Orbicular Pharmaceutical Technologies Pvt., Ltd. |
| Case Number | 3:25-cv-15336 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Sep 2025 – Mar 2026 6 months |
| Outcome | Settled – Confidential Terms |
| Patents at Issue | |
| Accused Products | Orbicular’s proposed Injectafer® (ferric carboxymaltose injection, 750 mg Iron/15 mL) generic |
Case Overview
The Parties
⚖️ Plaintiff
Swiss-based global pharmaceutical company specializing in iron deficiency therapies and nephrology products, holding a significant position in the intravenous iron market with Injectafer®.
🛡️ Defendant
Indian pharmaceutical manufacturer involved in generic drug development, targeting the Injectafer® formulation via an ANDA pathway.
Patents at Issue
This landmark case involved five U.S. patents protecting Injectafer® — the branded ferric carboxymaltose injection, covering the compound, formulation methods, and therapeutic applications.
- • US11433091B2 — Ferric carboxymaltose compound & formulation
- • US11478502B2 — Ferric carboxymaltose compound & formulation
- • US7754702B2 — Ferric carboxymaltose compound & formulation
- • US8895612B2 — Ferric carboxymaltose compound & formulation
- • US7612109B2 — Ferric carboxymaltose compound & formulation
Developing a generic injectable?
Check if your formulation might infringe these or related patents.
The Resolution & Legal Analysis
Outcome
The case was resolved through a **court-facilitated settlement conference** on March 10, 2026. Specific terms, including licensing or market entry dates, were not publicly disclosed. This outcome is consistent with confidential settlements common in Hatch-Waxman pharmaceutical patent litigation.
Key Legal Issues
The dispute was a standard **patent infringement claim** under the Hatch-Waxman Act, initiated by Vifor upon receiving a Paragraph IV certification from Orbicular. The relatively rapid closure (183 days) suggests both parties moved towards a negotiated resolution without proceeding to substantive claim construction or trial.
Developing new pharmaceutical formulations?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis in Pharma IP
This case highlights critical IP risks in specialty pharmaceutical development, particularly for complex injectables. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all patents covering ferric carboxymaltose
- See which companies are most active in injectable iron therapies
- Understand pharmaceutical claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic formulation or product.
- Input your generic formulation or API description
- AI identifies potentially blocking patents (including continuations)
- Get actionable infringement risk assessment report
High Risk Area
Ferric Carboxymaltose Formulations
5 Asserted Patents
Plus potential continuation chains
Formulation-Around Strategies
Possible with careful analysis
✅ Key Takeaways from Vifor v. Orbicular
For Pharmaceutical Patent Attorneys
Multi-patent assertions, especially with layered portfolios (compound, formulation, method-of-use), create significant leverage and often drive early settlement in Hatch-Waxman cases.
Search related Hatch-Waxman case law →New Jersey District Court remains a strategically favorable venue for innovator plaintiffs in pharmaceutical patent litigation.
Explore pharma litigation trends →For Pharma R&D & Regulatory Teams
Comprehensive Freedom-to-Operate analysis is crucial for generic drug development, considering continuation patent chains that extend protection beyond initial filings.
Start FTO analysis for my generic product →Robust patent portfolio development, including method-of-use and formulation claims, is vital for innovator companies protecting complex injectable products.
Try AI patent drafting for pharma →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.